Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SterisFRA:2TG -0.16%89 EV-to-EBIT is 21.68 as of Aug. 10, 2026, which is 26% below its 10-year median of 29.12. GuruFocus rates FRA:2TG with a GF Score™ of 89/100 and a GF Value™ of €217.43. The stock has 1 warning sign investors should review. Among 473 Medical Devices & Instruments companies, Steris ranks worse than 56.87% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Steris's Enterprise Value is €21,439 Mil.
Steris's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €989 Mil. Therefore, Steris's EV-to-EBIT for today is 21.68.
The historical rank and industry rank for Steris's EV-to-EBIT or its related term are showing as below:
FRA:2TG'
s EV-to-EBIT Range Over the Past 10 Years
Min: 17.46 Med: 29.12 Max: 132.52
Current: 21.36
During the past 13 years, the highest EV-to-EBIT of Steris was 132.52. The lowest was 17.46. And the median was 29.12.
FRA:2TG's EV-to-EBIT is ranked worse than 56.87% of 473
companies
in the Medical Devices & Instruments industry
Industry Median: 19.04
vs FRA:2TG: 21.36
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Steris's Enterprise Value for the quarter that ended in Jun. 2026 was €18,854 Mil.
Steris's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €989 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Steris EV-to-EBIT Related Terms
Steris EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Steris's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Steris's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Steris EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Steris's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Steris's EV-to-EBIT falls into.
Steris's current Enterprise Value is €21,439 Mil.
Steris's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €989 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Steris (FRA:2TG) has a EV-to-EBIT of 21.68 as of Aug. 10, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Steris and its competitors. This is 26% below median its historical median of 29.12. Over the past decade, Steris' EV-to-EBIT has ranged from 17.46 to 132.52. According to the industry distribution chart, Steris ranks #269 out of 473 companies in the Medical Devices & Instruments industry, placing it in the top 56.9%.
Is Steris' EV-to-EBIT too high?
Steris' current EV-to-EBIT of 21.68 is 26% below median its 10-year median of 29.12. Over the past 10 years, this metric has ranged from a low of 17.46 to a high of 132.52. The Medical Devices & Instruments industry median EV-to-EBIT is 19.04. Steris' value of 21.68 is 13.9% above this industry median. Based on the distribution chart, Steris ranks #269 out of 473 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Steris has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Steris' EV-to-EBIT compare to ZBH and GEHC?
According to the Medical Devices & Instruments industry distribution chart, Steris ranks #269 out of 473 companies for EV-to-EBIT. This places Steris in the lower half of its industry. The industry median EV-to-EBIT is 19.04. Steris' value of 21.68 is 13.9% above this benchmark. Historically, Steris' own EV-to-EBIT has ranged from 17.46 to 132.52 over the past decade. While the company's 10-year median is 29.12 vs. the industry median of 19.04, Steris has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.04, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Steris's current EV-to-EBIT of 21.68 is 13.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Steris and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Steris's current EV-to-EBIT is 21.68, which is 26% below median its own 10-year median of 29.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Steris stock overvalued right now?
Steris (FRA:2TG) has a current EV-to-EBIT of 21.68. The stock's GF Value™ is €217.43, compared to a current price of €192.20 — trading 11.6% below its estimated fair value. The current EV-to-EBIT is 21.68, which is 26% below median its 10-year median of 29.12 and 13.9% above the Medical Devices & Instruments industry median of 19.04. Steris' overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Steris (FRA:2TG), the current EV-to-EBIT is 21.68 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Steris (FRA:2TG) Overvalued in 2026?
Based on GuruFocus' analysis, Steris stock appears to be undervalued.
The current stock price of €192.20 is trading 11.6% below its estimated GF Value™ of €217.43.
Key valuation signals for FRA:2TG:
EV-to-EBIT: 21.68 (26% below median its 10-year median of 29.12)
GF Value™: €217.43 vs. price of €192.20 (11.6% below fair value)
Industry Position: 13.9% above the Medical Devices & Instruments median (#269 of 473)
No single metric tells the full story. See the FRA:2TG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 20% from Applied Sterilization Technologies, or AST, and 10% from life sciences services after the divestment of its dental products business.
89GF Score
Get the complete analysis for FRA:2TG
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2TG has been successfully added to your 
